Diabetes
-
Type 2 diabetes is a major risk factor for the development of cardiovascular disease and cerebrovascular incidents. A substantial body of evidence has demonstrated that the proper management of blood glucose in people with diabetes can inhibit the progression of microvascular diseases such as retinopathy and nephropathy.
Load moreType 2 diabetes is a major risk factor for the development of cardiovascular disease and cerebrovascular incidents. A substantial body of evidence has demonstrated that the proper management of blood glucose in people with diabetes can inhibit the progression of microvascular diseases such as retinopathy and nephropathy.
In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, the overall mortality significantly increased by strict control of blood glucose (target HbA1c <6%) compared with a less stringent control (target HbA1c of approximately 7%). Strict glucose control resulted in a significantly higher likelihood of developing severe hypoglycaemia, while severe hypoglycaemia was itself associated with death due to CVD.
Load Less
Videos
-
13 September 2017 -
13 September 2017 -
12 September 2017 -
27 August 2017 -
27 August 2017 -
25 July 2017
Pages
Type 2 Diabetes Mellitus
CV Outcomes in Diabetes
Risk reduction with antihyperglycemics
Cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D).
The opportunity for CV disease prevention in patients with T2D has recently expanded with antihyperglycemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE). Although the exact mechanisms of CV benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects. These agents have triggered a shift beyond glucose control, to a broader strategy of comprehensive CV risk reduction.
CV specialists are well-positioned to play a key role in managing patients with T2D including screening, aggressively treating CV risk factors, and incorporating the use of antihyperglycemic agents into routine practice.
The Radcliffe diabetes and CVD risk program is supported by an educational grant from Novo Nordisk.
Section Editor
Saint Luke's America Heart Institute, Kansas City, MO, US
-
Dario Giugliano, Maria Ida Maiorino, Miriam Longo, et alRecognizing that 12 CVOTs have been completed, we planned a systematic review and meta-analysis of CVOTs that evaluated the effect of GLP-1 RAs, DPP-4i, and SGLT2i on HF risk in patients with T2D.
AIM:
We performed...Endocrine. 2019 Apr 26. -
In terms of heart failure risk, sodium-glucose co-transporters 2 were the most favorable option among all classes of anti-diabetic medications.
BACKGROUND:
The cardiovascular (CV) safety in terms of heart failure among...Yang D, He X, Liang H, et al. Cardiovasc Diabetol 2019;18:47. -
Type 2 diabetes mellitus (T2DM) is a recognized risk factor for cardiovascular (CV) disease (CVD). In a large, prospective, cohort study of individuals ≥30 years of age, 18% of patients with diabetes developed incident CVD over 5.5 years of...
Cosentino F, Ceriello A, Baeres FMM, et al. Eur Heart J 2019;40:2907–19. -
Despite major therapeutic advances leading to improved outcomes over the past 2 decades, cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D) (1). Over that time, the prevalence...
Journal of the American College of Cardiology, ISSN: 1558-3597, Vol: 72, Issue: 24, Page: 3200-3223
Pages
Videos
-
31 Aug 2018 -
17 Apr 2018 -
14 Sep 2017 -
13 Sep 2017 -
13 Sep 2017
Pages
Clinical publications
-
Böhm M, Fitchett D, Ofstad AP, et al. J Hypertens 2020; eub ahead of press.
-
Davis WA, Gregg EW, Davis TME. J Clin Endocrinol Metab 2020;105:dgaa215.
-
Seong JM, Kim JJ, Kim HJ, Sohn HS. Cardiovasc Diabetol 2020;19:95.
-
Verma S, Ji Q, Bhatt DL, et al. Diabetes Obes Metab 2020;22:1207–14.
-
Cooper ME, Rosenstock J, Kadowaki T, et al. Diabetes Obes Metab 2020;22:1062–73.
-
Bajaj HS, Raz I, Mosenzon O, et al. Diabetes Obes Metab 2020;22:1122–31.
Pages
Ongoing trials
Pages
Review articles
-
Schernthaner G, Groop PH, Kalra PA, et al. Diabetes Obes Metab 2020;22:1024–34.
-
Ceriello A, Standl E, Catrinoiu D, et al. Diabetes Care 2020;43:1427–32.
-
Khunti K, Davies MJ, Seidu S. Expert Rev Pharmacoecon Outcomes Res 2020;20:237–49.
-
Mishriky BM, Okunrintemi V, Jain S, et al. Diabetes Metab 2020; epub ahead of press.
-
Sabouret P, Galati G, Angoulvant D, et al. Eur Heart J Cardiovasc Pharmacother 2020; epub ahead of press.
-
Chudleigh RA, Bain SC. Expert Rev Clin Pharmaco. 2020; epub ahead of press.
Pages
Guidelines
Pages
Congress Updates
-
Husain M, Bain SC, Holst AG, et al. Poster 1161-111 presented at ACC.20/WCC Virtual, 28 March 2020.
-
Jhund PS, Adamson C, Inzucchi SE, et al. Poster 1027-03 presented at ACC.20/WCC Virtual, 28 March 2020.
-
Verma S, Rasmussen S, Saevereid HA, Ripa MS. Circulation. 2019;140(Suppl 1):A11456.
-
Kosiborod MN, Jhund PS, Docherty KF, et al. Circulation. 2020;141:90–9.
-
Martinez FA, Serenelli M, Nicolau JC, et al. Circulation 2020;141:100–11.
-
Zelniker TA, Bonaca MP, Mosenzon O, et al. Circulation 2019;140(Suppl 1):A15581.
Pages
Pages
